Immunotherapeutic regimens in AML have been developed to enhance the antileukaemic potential of these cytotoxic lymphocytes. The notion that T and NK cells participate in the surveillance of leukaemic cells in AML is supported by studies suggestive of a positive correlation between T/NK-cell function and a favourable disease outcome. This correlation is evident from studies in allo-transplanted patients, in whom T/NK-cells clearly mediate the graft-versus-leukaemia effect that forms the basis for relapse prevention. 1, 2 A similar correlation has also been found in non-transplanted patients. [3] [4] [5] [6] [7] [8] [9] [10] A therapy that improves antileukaemic functions of T and NK cells would have the potential to reduce the relapse risk in AML. The most frequently studied compound in this regard is the T-and NK-cell-activating cytokine IL-2.
IL-2, which is produced by T cells and is pivotal to several aspects of cell- 
Panel A schematically describes how myeloid-cell-derived oxygen radicals inactivate antileukaemic lymphocytes and trigger apoptosis in these cells. Panel B shows the same scheme of events in the presence of histamine dihydrochloride (HDC), which inhibits oxygen radical production in myeloid cells and prevents these suppressive events. By maintaining the function and viability of antileukaemic lymphocytes, HDC synergises with the T-and NK-cell-activating cytokine interleukin (IL)-2 to induce killing of sensitive target cells, including human acute myeloid leukaemia blasts.

